Invention Grant
- Patent Title: Substituted oxazines as beta-secretase inhibitors
-
Application No.: US16466211Application Date: 2017-12-13
-
Publication No.: US10947223B2Publication Date: 2021-03-16
- Inventor: Jennifer R. Allen , Matthew P. Bourbeau , Ning Chen , Michael J. Frohn , Paul E. Harrington , Qingyian Liu , Corey Reeves
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agent Markus Bergauer
- International Application: PCT/US2017/066177 WO 20171213
- International Announcement: WO2018/112081 WO 20180621
- Main IPC: A61K31/535
- IPC: A61K31/535 ; A61K31/536 ; A61K31/537 ; C07D265/08 ; C07D265/12 ; C07D265/30 ; C07D413/10 ; A61P25/28 ; C07D413/14

Abstract:
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R2, R2′, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to beta amyloid (Aβ) plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
Public/Granted literature
- US20200207747A1 OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE Public/Granted day:2020-07-02
Information query